Predictive Vulnerability Intelligence.

Product

  • Product
  • Pricing
  • Documentation

Company

  • About
  • Partnerships
  • Blog
  • Support

Legal

  • Terms
  • Privacy
  • Data Licensing

© 2026 FAUCET Technologies LLC. All rights reserved.

CVE-2020-13461

14
FAUCET Score

CVE-2020-13461 describes a username enumeration vulnerability in all versions of Tufin SecureTrack. This medium-severity vulnerability (CVSS 4.3) allows an attacker on the internal network to discover valid usernames, with a low impact on confidentiality. Tufin has opted not to patch this issue, citing that internal network access already implies knowledge of usernames. There is no known public exploit code, active exploitation, or significant community discussion surrounding this CVE.

Impacted Technologies

VendorProductVersion(s)CPE
All Versions ImpactedCPE matchmatch criteria
cpe:2.3:a:tufin:securetrack:*:*:*:*:*:*:*:*

CVSS Data

CVSS version used by this source: 3.1

4.3MEDIUM

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

Attack Vector
ADJACENT_NETWORK
Attack Complexity
LOW
Privileges Required
NONE
User Interaction
NONE
Scope
UNCHANGED
Confidentiality Impact
LOW
Integrity Impact
NONE
Availability Impact
NONE
Exploitability Score
2.8
Impact Score
1.4
CvssVersion
3.1

Exploit Intelligence

EPSS Score
0.51%
Probability of exploitation in next 30 days
EPSS Percentile
40.4%
Percentile rank of EPSS score among Peer Group
As of 2026-07-25
Model: v2026.06.15
This CVE's current EPSS score of 0.0051 is in the 62nd percentile among its peer group of 1,802 CVEs.

Social Chatter

No social media mentions found for this CVE.

The average CVE in this peer group has 0.0 Twitter, 0.0 Reddit, 0.1 Bluesky, 0.0 Mastodon, and 0.1 GitHub mentions.

Media Mentions

No media coverage found for this CVE.

The average CVE in this peer group has 0.1 InfoSec Media, 0.0 Vendor Blog, and 0.0 Security Researcher mentions.

Remediation

Remediation records are not available for this CVE.

References

github.com / Accenture/AARO-Bugs/blob/master/AARO-CVE-List.md
Third Party Advisory